Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at

Articles by Eric Palmer

Merck unloads second EU plant as downsizing marches on

For the second time in two months, Merck & Co. has unloaded an API plant in Europe. This time it is a plant in France that it has sold to Luxembourg-based contract manufacturer Fareva.

Sun faces class action suit over closure of Caraco plants 6 years ago

It has been more than 6 years since Caraco Pharmaceutical Laboratories was forced to suddenly shut two Detroit-area manufacturing plants after the FDA sent in marshals to seize drugs, claiming the plants had contamination issues. One of the plants was even closed last year by Caraco owner Sun Pharmaceutical. But legal problems continue to reverberate for Sun for having laid off hundreds of workers without notice.

Sterilization specialist on expansion streak

Sterigenics International, which counts vaccine and API sterilization among its irradiation services, is expanding.

Woodcock says FDA will keep new plant quality grades a secret

The FDA publishes warning letters and inspection reports on its websites. It issues public recalls and drug label warnings. However, it is not feeling in such a sharing mood when it comes to its proposed letter grades for manufacturing plants on the quality of their manufacturing.

Shire works deal with Sanquin so it can boost production of rare disease drug

When Shire shelled out $4.2 billion for ViroPharma a couple of years ago, it picked up the rare disease drug Cinryze, but what it didn't get in the deal was complete control over manufacturing of the rare disease drug. That had been ceded by ViroPharma to Sanquin Blood Supply. But Shire has now worked a deal with Amsterdam-based Sanquin that will allow it to add more contract manufacturers and so boost production of the treatment.

UPDATED: Sucampo gets control of Amitiza production in deal for Japanese company

Sucampo sees a number of advantages to buying Japanese CDMO R-Tech Ueno, not the least of which will be owning the manufacturing for the two drugs that it sells.

Novo picks Clayton, NC, for its first U.S. API plant

Novo Nordisk has had filling, packaging and prefilled device manufacturing in Clayton, NC for years. Now the Danish drugmaker is betting its manufacturing future on the site. It will spend $1.2 billion on its first-ever U.S. API plant there and double the site's employment by adding 700 jobs.

Zoetis expands Nebraska facility even as its plots 10 plant closings

Animal health leader Zoetis has said that its massive cost-cutting plans will include whacking 10 unnamed manufacturing sites. But this week its manufacturing unit was taking solace in the expansion of one of its largest facilities.

China-based biotech to build manufacturing plant in Suzhou

With $97 million in angel investments and $14 million in milestone payments in hand, plus a pipeline of immuno-oncology drug candidates, China-based BeiGene believes it is time to look toward manufacturing.

Allergan pulls 55 lots of eye drugs after consumers find particulate in their eyes

Allergan Monday said it was going to pull some of its eye drugs from the market because of a problem with particles shedding from the tube cap which led to a "small number of customer complaints." The small number is nearly two dozen, including 12 consumers who said they had a foreign object in their eye as well as one report of swelling and another of blurred vision.